期刊文献+

偏头痛大鼠硬脑膜肥大细胞脱颗粒与神经源性炎症相关因子的变化 被引量:13

Changes on degranulation of mast cells and neurogenic inflammation-related factors in the dura mater of the rat model of migraine
原文传递
导出
摘要 目的观察偏头痛大鼠硬脑膜肥大细胞脱颗粒与神经源性炎症相关因子的变化,探讨偏头痛疼痛产生的可能机制。方法64只SD大鼠随机分为刺激组(32只)和假手术组(32只)。电刺激大鼠单侧三叉神经节建立偏头痛模型,放射免疫法测定刺激侧颈静脉血中降钙素基因相关肽(CGRP)的含量。酶联免疫吸附法测定刺激侧颈静脉血中组胺和硬脑膜中前列腺素E2(PGE2)的含量,甲苯胺蓝染色观察硬脑膜肥大细胞的数量及脱颗粒百分率,免疫组织化学染色法、免疫蛋白质印迹技术观察硬脑膜中环氧化酶-2(COX-2)的阳性细胞数及蛋白表达。结果假手术组和刺激组颈静脉血中CGRP含量分别为(59.20±11.66)pg/ml和(82.84±16.24)pg/ml(t=-3.34);组胺含量分别为(9.87±0.88)ng/ml和(11.59±1.20)ng/ml(t=-3.27);硬脑膜中肥大细胞数量分别为15.46±2.40和11.63±1.67(t=3.71),脱颗粒百分率分别为14.09%±4.53%、29.10%±9.39%(t=-4.07)。两组硬脑膜中PGE:的含量分别为(80.70±10.60)pg/ml和(382.30±20.90)pg/ml(t=-16.674);硬脑膜中COX-2阳性细胞数分别为42.00±18.40和139.00±20.50(t=-7.994),COX-2蛋白表达(吸光度值)分别为19.50±9.20和359.20±21.90(t=-5.190)。两组间比较,上述指标差异均有统计学意义(P〈0.05)。结论电刺激单侧三叉神经节可诱导硬脑膜肥大细胞脱颗粒及神经源性炎症的产生,相关炎症因子的改变可能是偏头痛疼痛发生的重要病理生理基础。 Objective To observe the changes on the neurogenic inflammation-related factors in the dura mater of the rat model of migraine and investigate the possible mechanism of the pain of migraine. Methods SD rats were randomly divided into stimulation group ( n = 32 ) and sham group ( n = 32 ). Unilateral trigeminal ganglion was stimulated to induce migraine for rats in the stimulation group. Rats in the sham group were subjected to sham surgery. The levels of calcitonin gene-related peptide (CGRP) in the blood of jugular vein in the stimulation side were measured by radioimmunoassay. The levels of histamine in peripheral blood and prostaglandin E2 (PGE2 ) in the dura mater were determined by enzyme-linked immunosorbent assay (ELISA). The number of mast cells and percentage of their degranulation in the dura mater were determined under a microscope after toluidine blue staining. Cyclooxygenase 2 (COX-2) expression in the dura mater was evaluated by immunohistochemical staining and western blot analysis. Results In the stimulation group, the level of CGRP in the ipsilateral jugular vein was (82. 84 ± 16. 24) pg/ml and in the sham group was (59. 20 ± 11.66) pg/ml (t = -3.34, P 〈0. 05). The level of histamine in the ipsilateral jugular vein was ( 11.59 ± 1.20) ng/ml and in the sham group was (9. 87 ±0. 88) ng/ml (t = -3.27, P 〈 0. 05 ). The number of mast cells in the dura mater decreased from 15.46 ± 2.40 in the stimulation group to 11.63 ±1.67 in the sham group (t =3.71, P 〈0. 05). Degranulation of mast cells in the dura mater significantly increased from 14. 09% ±4. 53% in the sham group to 29. 10% ±9. 39% in the stimulation group (t = -4. 07, P 〈 0. 05). The level of PGE2 in the stimulation group was (382. 30 ± 20. 90) pg/ml and in the sham group was (80.70 ± 10. 60) pg/ml (t = - 16. 674, P 〈0. 05). The number of COX-2 positive cells significantly increased from 42. 00 ± 18. 40 in the sham group to 139.00±20. 50 in the stimulation group (t = -7. 994, P 〈0.05). Also the COX-2 protein level was elevated from 19. 50 ± 9. 20 in the sham group to 359. 20± 21.90 in the stimulation group (t = -5. 190, P 〈 0. 05 ). Conclusions Electrical stimulation on the unilateral trigeminal ganglion induces neurogenie inflammation in the dura mater. Changes on the neurogenie inflammation-related factors are probably the essential pathophysiologieal mechanism underlying the pain in migraine.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2011年第8期563-567,共5页 Chinese Journal of Neurology
关键词 偏头痛 肥大细胞 降钙素基因相关肽 地诺前列酮 环氧化酶2 Migraine disorders Mast cells Calcitonin gene-related peptide Dinoprostone Cyelooxygenase 2
  • 相关文献

参考文献20

  • 1偏头痛诊断与防治专家共识组,李焰生.偏头痛诊断与防治专家共识[J].中华内科杂志,2006,45(8):694-696. 被引量:322
  • 2Knyihar-Csillik E, Tajti J, Chadaide Z, et al. Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. Microsc Res Tech, 2001, 53: 193-211.
  • 3v Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci, 2003, 4: 386-398.
  • 4Goadsby PJ. Recent advances in understanding migrainemechanisms, molecules and therapeutics. Trends Mol Med, 2007, 13 : 39-44.
  • 5Moskowitz MA. Pathophysiology of Headache--past and present. Headache, 2007, 47 Suppl 1: $58-63.
  • 6Limmroth V, Katsarava Z, Liedert B, et al. An in vivo rat model to study calcitonin generelated peptide release following activation of the trigeminal vascular system. Pain, 2001, 92: 101-106.
  • 7Lennerz JK, ROhle V, Ceppa EP, et al. Calcitonin receptor-like receptor ( CLR), receptor activity-modifying protein 1 ( RAMP1 ), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol, 2008, 507 : 1277-1299.
  • 8Dan L. Meningeal mast cells, inflammation and migraine pain. Drug Development Research, 2007, 68 : 412-418.
  • 9Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia, 1997, 17: 166-174.
  • 10Schwenger N, Dux M, de Col R, et al. Interaction of calcitonin gene-related peptide, nitric oxide and histamine release in neurogenic blood flow and afferent activation in the rat cranial dura mater. Cephalalgia, 2007, 27: 481-491.

二级参考文献16

  • 1Lipton RB,Diamond S,Reed M,et al.Migraine diagnosis and treatment:results from the American Migraine Study Ⅱ.Headache,2001,41:638-645.
  • 2Silberstein SD.Practice parameter:evidence-based guidelines for migraine headache (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology,2000,55:754-762.
  • 3Ferrari MD,Roon KI,Lipton RB,et al.Oral triptans (serotonin 5-HT(1B/1 D) agonists) in acute migraine treatment:a meta-analysis of 53 trials/ Lancet,2001,358:1668-1675.
  • 4Headache Classification Subcommittee of the International Headache Society.The Internatiional Classificatiion of Headache Disorders:2nd edition.Cephalalgia,2004,24 Suppl 1:9-160.
  • 5Lawrence EC.Diagnosis and management of migraine headaches.South Med J,2004,97:1069-1077.
  • 6Goadsby PJ,Lipton RB,Ferrari MD.Migraine-current understanding and treatment.N Engl J Med,2002,346:257-270.
  • 7Lipton RB,Stewart WF,Stone AM,et al.Stratified care vs step care strategies for migraine:the Disablility in Strategies of Care(DISC) Study:A randomized trial.JAMA,2000,284:2599-2605.
  • 8Lipton RB,Bigal ME.Migraine:epidemiology,impact,and risk factors for progression.Headache,2005,45:Suppl 1:S3-S13.
  • 9Silberstein SD,Rosenberg J.Multispecialty consensus on diagnosis and treatment of headache.Neurology,2000,54:1553.
  • 10Snow V,Weiss K,Wall EM,et al.Pharmacologic management of acute attacks of migraine and prevention of migraine headache.Ann Intern Med,2002,137:840-849.

共引文献364

同被引文献143

引证文献13

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部